Intelligent Bio Solutions Inc. logo

Intelligent Bio Solutions Inc.(INBS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 1 day
PROFIT SINCE LAST BUY
-21.78% ▼
LAST CLOSE
$1.76
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INBS

11/13/2026: INBS (1-star) is a SELL. SELL for 1 day. Simulated Profits (-21.78%). Updated daily EoD!

Intelligent Bio Solutions Inc. is a medical technology micro-cap that specializes in non-invasive workplace drug testing through its proprietary Intelligent Fingerprinting system. The company relies on a razor-and-razorblade model, driving revenue growth through portable reader placements and higher-margin consumable cartridge reorders in international markets. Key strengths include accelerating revenue scale, improving gross margins, and expanding active customer accounts in safety-critical sectors. However, the investment story carries notable risks, including persistent net losses, cash burn, dilution from warrants, and heavy reliance on pending U.S. FDA regulatory clearance. The stock suits high-risk speculative or momentum-oriented investors willing to monitor regulatory catalysts and cash management closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitRapid top-line revenue expansion appeals to growth goals, but early-stage scale and losses temper the overall fit.
Momentum investorStrong fit while signal remains positiveMicro-cap volatility and news-driven catalysts around FDA updates can create sharp, short-term trading momentum.
Value investorWeak fitOngoing net losses, negative earnings, and unprofitability eliminate traditional value appeal.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into commercial scaling.
Low-risk investorWeak fitHigh share price volatility, financing dilution risks, and going-concern considerations make it unsuitable for risk-averse profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow market capitalization and low float frequently drive dramatic intraday and periodic price swings.
Valuation riskMedium / highPricing is largely sentiment-driven given the absence of positive GAAP net income or traditional earnings multiples.
Competition risk (legacy diagnostics and alternative testing platforms)HighEstablished players dominate mainstream drug screening channels, making market share acquisition challenging.
Business qualityMediumThe razor-and-razorblade business model exhibits promising gross margins, but the broader operating framework is still maturing.
Dividend incomeLow / noneNo dividend distributions are made or anticipated in the near term.
Execution riskHighSuccess relies heavily on securing regulatory clearances, scaling international adoption, and managing capital burn.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.84M USD
Price to earnings Ratio -
1Y Target Price 12
Price to earnings Ratio -
1Y Target Price 12
Volume (30-day avg) 47.3K shares
Beta 4.49
52 Weeks Range 1.35 - 24.90
Updated Date 11/15/2026
52 Weeks Range 1.35 - 24.90
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -8.44

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -69.05%
Avg. Invested days 8
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INBS receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
INBS has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2026 versus FY2025, strong revenue growth (+38.1%) is partially offset by negative earnings growth (-17.6%), weak cash generation (FCF margin -285.9%), weak profitability (net margin -294.9%).

Financial Health Rating

★★★★★
INBS's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 18.2%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is INBS's strongest growth driver at +38.1% FY2026 versus FY2025 (strong, 5 stars). By comparison, while earnings growth (-17.6%, negative) and free-cash-flow growth (-21.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 5.8% (soft) and 97.0% of outstanding shares are publicly tradable (strong). Insider ownership of 2.74% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Armistice Capital, LLC 4.26%
Geode Capital Management, LLC 0.63%
Vanguard Capital Management, LLC 0.18%
UBS Group AG 0.17%
Vanguard Fiduciary Trust Co 0.12%

Unit Economics (Per $1K Revenue)

★★★★★
INBS generates approximately $486 of gross profit, $-2,991 of operating income, and $-2,859 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.30%

Quantitative Style Profile

★★★★★
INBS has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Consumable Cartridge SalesSingle-use disposable test cartridges utilized during each fingerprint screening test, generating recurring revenue.This is the core recurring revenue engine of their razor-and-razorblade business model.
Handheld Readers and HardwareSales and placements of the portable electronic reading units used to analyze test cartridges on-site.Hardware placements build the active customer installed base which drives future consumable orders.
International Markets (UK and Global)Commercial distribution and service deployment across safety-sensitive industries primarily outside the United States.International adoption currently provides the majority of the company's operating revenue.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3.66M
Price to Sales(TTM) 1.3
Enterprise Value 3.66M
Price to Sales(TTM) 1.3
Enterprise Value to Revenue 0.87
Enterprise Value to EBITDA -0.91
Shares Outstanding 3.32M
Shares Floating 3.22M
Shares Outstanding 3.32M
Shares Floating 3.22M
Percent Insiders 2.74
Percent Institutions 5.77

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.